{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T07:29:48Z","timestamp":1761290988049},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,6,28]],"date-time":"2014-06-28T00:00:00Z","timestamp":1403913600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s10620-014-3247-7","type":"journal-article","created":{"date-parts":[[2014,6,27]],"date-time":"2014-06-27T05:32:33Z","timestamp":1403847153000},"page":"2821-2825","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Predictors of Mortality in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization"],"prefix":"10.1007","volume":"59","author":[{"given":"Pranab M.","family":"Barman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratima","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkat","family":"Krishnamurthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathon","family":"Willatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"McCurdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard H.","family":"Moseley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace L.","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,28]]},"reference":[{"key":"3247_CR1","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1111\/j.1872-034X.2007.00168.x","volume":"37","author":"HBE Serag","year":"2007","unstructured":"Serag HBE. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res. 2007;37:S88\u2013S94.","journal-title":"Hepatol Res"},{"key":"3247_CR2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/MCG.0b013e3182872f29","volume":"47","author":"S Mittal","year":"2013","unstructured":"Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47:S2\u2013S6.","journal-title":"J Clin Gastroenterol"},{"key":"3247_CR3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/hep.23615","volume":"52","author":"JA Davila","year":"2010","unstructured":"Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010;52:132\u2013141.","journal-title":"Hepatology"},{"key":"3247_CR4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1158\/1055-9965.EPI-11-1005","volume":"21","author":"AG Singal","year":"2012","unstructured":"Singal AG, Conjeevaram HS, Volk ML, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomark Prev. 2012;21:793\u2013799.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"3247_CR5","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10620-010-1453-5","volume":"56","author":"P Sharma","year":"2011","unstructured":"Sharma P, Saini SD, Kuhn LB, et al. Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists. Dig Dis Sci. 2011;56:569\u2013577.","journal-title":"Dig Dis Sci"},{"key":"3247_CR6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/MOG.0b013e32835ff1cf","volume":"29","author":"KT Padhya","year":"2013","unstructured":"Padhya KT, Marrero JA, Singal AG. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol. 2013;29:285\u2013292.","journal-title":"Curr Opin Gastroenterol"},{"key":"3247_CR7","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"J Bruix","year":"2011","unstructured":"Bruix J, Sherman M, American D. Association for the Study of Liver Diseases, Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020\u20131022.","journal-title":"Hepatology"},{"key":"3247_CR8","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1055\/s-0033-1333631","volume":"33","author":"JA Marrero","year":"2013","unstructured":"Marrero JA. Multidisciplinary management of hepatocellular carcinoma: where are we today? Semin Liver Dis. 2013;33:S3\u2013S10.","journal-title":"Semin Liver Dis"},{"key":"3247_CR9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52\u201360.","journal-title":"Semin Liver Dis"},{"key":"3247_CR10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3747\/co.v18i5.952","volume":"18","author":"M Sherman","year":"2011","unstructured":"Sherman M, Burak K, Maroun J, et al. Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol. 2011;18:228\u2013240.","journal-title":"Curr Oncol"},{"key":"3247_CR11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nrgastro.2012.199","volume":"10","author":"A Villanueva","year":"2013","unstructured":"Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol. 2013;10:34\u201342.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3247_CR12","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s12072-011-9276-9","volume":"5","author":"YJ Tsai","year":"2011","unstructured":"Tsai YJ, Hsu CY, Huang YH, et al. Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. Hepatol Int. 2011;5:975\u2013984.","journal-title":"Hepatol Int"},{"key":"3247_CR13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1365-2036.2011.04694.x","volume":"34","author":"G Cabibbo","year":"2011","unstructured":"Cabibbo G, Genco C, Di Marco V, et al. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. Aliment Pharmacol Ther. 2011;34:196\u2013204.","journal-title":"Aliment Pharmacol Ther"},{"key":"3247_CR14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-2036.2007.03395.x","volume":"26","author":"H Shen","year":"2007","unstructured":"Shen H, Agarwal D, Qi R, et al. Predictors of outcome in patients with unresectable hepatocellular carcinoma receiving transcatheter arterial chemoembolization. Aliment Pharmacol Ther. 2007;26:393\u2013400.","journal-title":"Aliment Pharmacol Ther"},{"key":"3247_CR15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","volume":"37","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429\u2013442.","journal-title":"Hepatology"},{"key":"3247_CR16","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Monta\u00f1a X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734\u20131739.","journal-title":"Lancet"},{"key":"3247_CR17","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"CM Lo","year":"2002","unstructured":"Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164\u20131171.","journal-title":"Hepatology"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-014-3247-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-014-3247-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-014-3247-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T19:44:17Z","timestamp":1559245457000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-014-3247-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,28]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["3247"],"URL":"https:\/\/doi.org\/10.1007\/s10620-014-3247-7","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,28]]}}}